Device Trial Radar · NCT02506465
Pivotal Study to Assess the Safety and Effectiveness of the iTind Device
Last checked: Nov 19, 2026Latest source record: Feb 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
185
Actual
Start
Jul 2015
Primary completion
Oct 2018
Study completion Oct 2018
Sponsor
- Lead sponsor
- Medi-Tate Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 23, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- Male only, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study objectives are to demonstrate the efficacy and safety of the Medi-Tate iTIND as compared to control group (catheter only).
Conditions
- Benign Prostate Hyperplasia
Interventions
iTINDDevice
Temporary Implantable Nitinol Device (iTIND)
Sham ArmProcedure
Foley catheter will be placed and immediately removed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Month 3 Results in the IPSS Score in Both Arms.Time frame: 3 months
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Research Center of Florida
Pompano Beach, Florida
Chesapeake Urology Research Associates
Baltimore, Maryland
Methodist Hospital
Brooklyn, New York
10 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.